Referenzen
Produkte Transfektion
Kostenlose Testsamples
Anwendungshinweise:
Im „Transfection Reagent Selection Guide“ können Sie durch Filterfunktionen z.B. für Ihre Kombination aus zu transfizierender Zelle und Nukleinsäure die Liste vorhandener Referenzen durchsuchen. Ebenso können Sie im Feld „Referenzen durchsuchen“ am Anfang der Seite mit passenden Schlagwörtern zu einem Ergebnis gelangen. Eine Referenz zeigt an, dass das gefundene Transfektionsreagenz bereits erfolgreich für die entsprechende Anwendung verwendet wurde. Im Idealfall sind getestete Transfektionsparameter und Transfektionseffizienzen angegeben.
Keine Referenz? > Allgemeine Auswahlhilfe
Wenn Sie keine Referenz gefunden haben, heißt das nicht, dass kein passendes Reagenz zur Verfügung steht, sondern lediglich, dass bisher keine Erfahrungsberichte vorliegen. In diesem Falle kann durch eine Vorauswahl ein erfolgsversprechendes Transfektionsreagenz ausgewählt (Allgemeine Auswahlhilfe) und letztendlich ausgetestet (Kostenlose Testsamples) werden. Wenn Sie einen Erfahrungsbericht für uns schreiben möchten machen wir Ihnen ein Angebot für eine Gegenleistung.
CELL TYPE | DESCRIPTION OF CELL TYPE | CAT.NO. | SPECIES | ORIGIN OF CELLS | COMMON CELL TYPE | GROWTH PROPERTIES | NUCLEIC ACID / DELIVERED MOLECULE | APPLICATION | PRODUCT | REFERENCE TYPE | BIBLIOGRAPHIC DATA | LINK | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
6E4 HeLaT |
Human cervix adenocarcinoma cell line (derivative of HeLa) | Human | genital tract | cell line | adherent | plasmid | cotransfection (plasmid/sgRNA) | Metafectene | publication | D. Kim et al., Nat ure Struct ural & Molec ular Biology, 2020, 27: 581–588, doi.org/10.1038/s41594-020-0427-3 | |||
6E4 HeLaT |
Human cervix adenocarcinoma cell line (derivative of HeLa) | Human | genital tract | cell line | adherent | plasmid | CRISPR | Metafectene | publication | D. Kim et al., Nat ure Struct ural & Molec ular Biology, 2020, 27: 581–588, doi.org/10.1038/s41594-020-0427-3 | |||
786-O |
Human renal adenocarcinoma cell line | ATCC CRL-1932 | Human | urinary system | cell line | adherent | plasmid | Metafectene PRO | publication | E. Alcaraz, Dissertation, 2015, University of Barcelona | |||
8505C |
Human papillary thyroid cancer cell line | Human | other | cell line | adherent | plasmid | Metafectene PRO | publication | V. Vella et al., Endocrine-Related Cancer, 2019, 197–214, 26: 1, doi.org/10.1530/ERC-18-0310 | Link | |||
92.1 |
Human uveal melanoma cell line | Human | skin | cell line | adherent | plasmid | Metafectene PRO | publication | I. Venza et al., Int. Immunopharmacol., 2014, 21: 439–446; doi.org/10.1016/j.intimp.2014.05.024 | ||||
A-2058 |
Human skin melanoma cell line | ATCC CRL-11147 | Human | skin | cell line | adherent | plasmid | Metafectene | publication | E. Cesaro et al., Research Square, 2021, DOI: https://doi.org/10.21203/rs.3.rs-278700/v1 | Link | ||
A-2058 |
Human skin melanoma cell line | ATCC CRL-11147 | Human | skin | cell line | adherent | plasmid | K2 Transfection System | application note | ![]() |
|||
A-2058 |
Human skin melanoma cell line | ATCC CRL-11147 | Human | skin | cell line | adherent | plasmid | RNA-Interference | Metafectene | publication | E. Cesaro et al., Research Square, 2021, DOI: https://doi.org/10.21203/rs.3.rs-278700/v1 | Link | |
A-2780 |
Human ovarian carcinoma cell line | Human | genital tract | cell line | adherent | plasmid | stable transfection | Metafectene PRO | publication | C.F.T. Taute, PhD Thesis, 2013, University of the Western Cape | Link | ||
A-2780 |
Human ovarian carcinoma cell line | Human | genital tract | cell line | adherent | plasmid | Metafectene PRO | publication | C. P. Masamha et al., Cancer Res., Aug 2009; 69: 6565 - 6572 | Link | |||
A375 |
Human skin malignant melanoma cell line | ATCC CRL-1619 | Human | skin | cell line | adherent | plasmid | stable transfection | K2 Transfection System | publication | M. Tufano et al., Front. Cell Dev. Biol., 2021, 9: 718947, doi: 10.3389/fcell.2021.718947 | Link | |
A375 |
Human skin malignant melanoma cell line | ATCC CRL-1619 | Human | skin | cell line | adherent | plasmid | Metafectene | publication | D. Kobelt et al., Mol. Oncology, 2014, 8: 209-619, doi.org/10.1016/j.molonc.2013.12.019 | Link | ||
A375 |
Human skin malignant melanoma cell line | ATCC CRL-1619 | Human | skin | cell line | adherent | plasmid | Metafectene | publication | A. Y. Filatova et al., Eur. J. of Human Genetics, 2019, 27: 488–493, doi.org/10.1038/s41431-018-0288-y | Link | ||
A375 |
Human skin malignant melanoma cell line | ATCC CRL-1619 | Human | skin | cell line | adherent | plasmid | CRISPR | K2 Transfection System | publication | M. Tufano et al., Front. Cell Dev. Biol., 2021, 9: 718947, doi: 10.3389/fcell.2021.718947 | Link | |
A375 |
Human skin malignant melanoma cell line | ATCC CRL-1619 | Human | skin | cell line | adherent | plasmid | K2 Transfection System | application note | ![]() |
|||
A375 |
Human skin malignant melanoma cell line | ATCC CRL-1619 | Human | skin | cell line | adherent | plasmid | RNA-Interference | K2 Transfection System | publication | M. Tufano et al., Front. Cell Dev. Biol., 2021, 9: 718947, doi: 10.3389/fcell.2021.718947 | Link | |
A375 |
Human skin malignant melanoma cell line | ATCC CRL-1619 | Human | skin | cell line | adherent | plasmid | Metafectene | publication | D. Kobelt, Dissertation, 2012, Humboldt-Universität zu Berlin | Link | ||
A375 |
Human skin malignant melanoma cell line | ATCC CRL-1619 | Human | skin | cell line | adherent | plasmid | Metafectene | publication | A. Y. Filatova et al., Europ. J. of Human Genetics, 2019, 27: 488–493 | |||
A375 |
Human skin malignant melanoma cell line | ATCC CRL-1619 | Human | skin | cell line | adherent | plasmid | Metafectene | publication | E. Cesaro et al., Research Square, 2021, DOI: https://doi.org/10.21203/rs.3.rs-278700/v1 | Link | ||
A375 |
Human skin malignant melanoma cell line | ATCC CRL-1619 | Human | skin | cell line | adherent | plasmid | cotransfection (plasmid/plasmid) | K2 Transfection System | publication | M. Tufano et al., Front. Cell Dev. Biol., 2021, 9: 718947, doi: 10.3389/fcell.2021.718947 | Link | |
A375 |
Human skin malignant melanoma cell line | ATCC CRL-1619 | Human | skin | cell line | adherent | plasmid | Metafectene | publication | S. Romano et al., Pigment Cell Melanoma Res., 2013, 26: 900–911, doi: 10.1111/pcmr.12144 | |||
A375 |
Human skin malignant melanoma cell line | ATCC CRL-1619 | Human | skin | cell line | adherent | plasmid | Metafectene PRO | application note | ![]() |
|||
A375 |
Human skin malignant melanoma cell line | ATCC CRL-1619 | Human | skin | cell line | adherent | plasmid | Metafectene | publication | D. Kobelt et al., Mol. Biotechnol., Mol Biotechnol, 2013, 53:80-89 | |||
A375 |
Human skin malignant melanoma cell line | ATCC CRL-1619 | Human | skin | cell line | adherent | plasmid | K2 Transfection System | publication | M. Tufano et al., Front. Cell Dev. Biol., 2021, 9: 718947, doi: 10.3389/fcell.2021.718947 | Link | ||
A375 |
Human skin malignant melanoma cell line | ATCC CRL-1619 | Human | skin | cell line | adherent | plasmid | RNA-Interference | Metafectene | publication | E. Cesaro et al., Research Square, 2021, DOI: https://doi.org/10.21203/rs.3.rs-278700/v1 | Link |